Loading
Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a new treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac. Monopar builds its drug development pipeline through in-house efforts and licensing of late preclinical and clinical-stage therapeutics, leveraging its scientific and clinical expertise to reduce risk and accelerate development.

Monopar's team is located in San Francisco, CA and Chicago, IL.

Why Oncology?

Monopar is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers.

Why Rare Disease?

Monopar recently in-licensed bis-choline tetrathiomolybdate (ALXN1840), a late-stage investigational drug to treat Wilson Disease.

Corporate Overview

Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization. 

Our Research Pipeline

Monopar's pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac.



Product Indications Discovery Preclinical Phase 1 Phase 2 Phase 3 Status

MNPR‑101‑Zr (Oncology)

Advanced Solid Cancers (Imaging)

Discovery complete

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Phase 1 Clinical Trial Active and Recruiting

MNPR-101-Lu (Oncology)

Advanced Solid Cancers

Discovery complete

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Phase 1a Clinical Trial Active and Recruiting

MNPR-101-Ac (Oncology)

Advanced Solid Cancers

Discovery complete

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Late Preclinical

Early Pipeline (Oncology)

Solid cancers

Discovery complete

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Early Preclinical

Early Pipeline (Oncology)

Solid cancers

Discovery in progress

Preclinical not started

Phase 1 not started

Phase 2 not started

Phase 3 not started

Discovery

ALXN1840 (Rare Disease)

Wilson Disease

Discovery complete

Preclinical complete

Phase 1 complete

Phase 2 complete

Phase 3 in progress

Phase 3 - Primary Endpoint Met  Phase 2 - MOA Inconclusive, Endpoints Not Met
Email Alerts

Stay informed and receive company updates straight to your inbox